

Dear Controlled Release Society community,

My name is Bruno Sarmiento and I am Principal Investigator at [Institute for Research and Innovation in Health](#) (i3S) – University of Porto, the largest research center on biomedical and health sciences in Portugal. I am also Professor of Drug Delivery at the University Institute of Health Sciences in Portugal. I gained my PhD from the University of Porto in 2007 – with long-term residences at



Queen's University (Canada), Copenhagen University (Denmark) and University of Santiago de Compostela (Spain) – developing innovative polymer-based nanoformulations for oral delivery of insulin.

I was appointed Professor in 2008 and entered i3S as Group Leader in 2012. I am member of the Board of Directors of my institute since 2019.

My research work is focused on the development of drug delivery systems, with special emphasis on nanotechnology, and their application to the pharmaceutical and biomedical fields. I am interested in engineering targeted nanomedicines by identifying novel biological targets, proposing new functional ligands and producing tailored nanoplatforms for the delivery of therapeutic molecules for managing cancer, infection and metabolic diseases. My research has been pivotal for understanding the mechanism of transport of nanoparticles at the tissue and cellular levels, and for the establishment of the advantageous features of different nanosystems for prevention, diagnostics and therapy. In particular, I am committed to unraveling the real value of “nano” for mucosal drug delivery by developing mucodiffusive, molecularly bioengineered nanoparticles for the oral delivery of antidiabetic peptides, establishing advanced multistage functionalized nanoparticles for cancer diagnostic and treatment, and developing nanotechnology-based formulations for preventing and treating infectious diseases. I also gained specialized knowledge in 3D tissue engineering models to validate functionalized nanomedicines and to establish in vitro/in vivo correlation.

My research is aimed at translating academic knowledge into the industry. For that, I have established several collaboration agreements with international companies and participated as an entrepreneur in the creation of spin-offs. My work has attracted funding of over 15 million Euros, from public and private entities, and pharmaceutical and medical devices industries.

I published more than 370 papers (total citations over 17,000 and H-index 64) and was invited speaker in some of the most prestigious international scientific meetings in delivery science. I have also been strongly committed in mentoring new generations of scientists, which translated into the direct supervision of 45 PhD students and 14 post-doctoral fellows throughout my career, all of whom shared their research at CRS Annual Meetings.


The CRS has been a persisting presence in my scientific path. My involvement with the CRS started in 2006, still as a PhD student. Since my first CRS Annual Meeting in that same year, I have been able to learn from the best in delivery science, staying in touch with the latest developments in the field, establishing a network of longstanding collaborators and shaping my own research work. My ties with the Society grew even stronger over recent years, when I was invited to be the first Chair of the Nanomedicine and Nanoscale Drug Delivery Focus Group (2018-2019), elected as board member and vice-president of the Spanish-Portugal CRS Local Chapter (2018-2022), and nominated as CRS Ambassador for Brazil (since 2019) and as Chair of the International Chapter Committee (since 2021). I am currently serving on the 2021 Annual Meeting Program Committee as Vice-Chair for Technical Programming. I also play an active role on the Society's official journals, namely as an Editorial Board Member of the Journal of Controlled Release (since 2018) and as an Associate Editor of Drug Delivery and Translational Research (since 2019).

I often find myself wondering about what makes the CRS so special, and why did I always felt so passionate and drawn into it. I believe that the greatest asset of CRS lies on its community. Vibrant, diverse, inclusive! It is not just a group of exceling scientists and entrepreneurs conducting incredible, cutting-edge science. It is much more than that. The people involved in the Society – from young researchers to its president – embody the best there is in science, based upon strong ethical principles, collaborative spirit and critical scrutiny. It is this sense of community spirit that I pledge to defend and expand as Director-at-Large. I strongly believe that my dedication to and knowledge of the Society and its individuals will be invaluable for contributing to its mission.

My commitment will be with the CRS and its members. My goal is to work, in strong and loyal collaboration, with the members of the Board of Directors, for a stronger appreciation and increased add-value of all members of Society. My vision is strengthen the CRS as the main international scientific organization dedicated to delivery science and technology, ultimately providing resources, training, translation and dissemination actions to improve the quality life worldwide.

Please follow my visions, positions and statements through my [Twitter](#), [LinkedIn](#) and [Facebook](#).

Kind regards,



Bruno Sarmiento, PhD, University of Porto, Portugal